Supplementary figure 1: Y-27632 treatment does not affect cell viability A) Cell viability measured using a metabolic colorimetric assay; CellTiter (Promega) shows no decrease in viability on treatment of BT549 and Hs578T cells with 10μM Y-27632 for 1 hour or 24 hours. Columns represent averaged values of 3 independent experiments done in triplicate, normalized over vehicle-control B) Representative western blot image of attached and suspended BT549 and Hs578T cells treated with 10μM Y-27632 [RI] for 1 hour shows absence of PARP cleavage (N=3). BT549 cells treated with 0.5µM staurosporine for 1 hour was used as a positive control for PARP cleavage.
Supplementary figure 2: Rho Activator II treatment does not affect cell viability
A) Cell viability measured using a metabolic colorimetric assay; CellTiter (Promega) shows no decrease in viability of BT549 or Hs578T cells on treatment with 4μg/ml Rho Activator II for 3 hours or 24 hours. Columns represent averaged values of 3 independent experiments done in triplicate, normalized over vehicle-control. B) Representative western blot image of attached and suspended BT549 and Hs578T cells treated with 4μg/ml Rho Activator II [RA] for 3 hours shows absence of PARP cleavage (N=3). BT549 cells treated with 0.5µM staurosporine for 1 hour was used as a positive control for PARP cleavage.
Supplementary figure 3: Colchicine treatment reduces reattachment of cells from suspension
Phase contrast images of A) BT549 and B) Hs578T cells treated for an hour with vehicle control or 10μM Y-27632 or 50μM colchicine or a combination of 10μM Y-27632 and 50μM colchicine show differences in reattachment efficiencies of cells from each treatment group following detachment. Cells treated with 10μM Y-27632 reattach more efficiently compared to vehicletreated group. 50μM colchicine treatment significantly reduces the reattachment frequency of cells when used singly or in combination with Y-27632 (10x magnification).
